Mattern Capital Management LLC Acquires 1,843 Shares of Becton, Dickinson and Company (NYSE:BDX)

Mattern Capital Management LLC raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,359 shares of the medical instruments supplier’s stock after purchasing an additional 1,843 shares during the quarter. Mattern Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $7,341,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its holdings in shares of Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after acquiring an additional 1,317,723 shares during the last quarter. Nordea Investment Management AB lifted its holdings in shares of Becton, Dickinson and Company by 31.0% in the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock worth $647,082,000 after acquiring an additional 673,568 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Becton, Dickinson and Company by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock worth $1,293,635,000 after acquiring an additional 460,440 shares during the last quarter. Vaughan Nelson Investment Management L.P. bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth about $108,243,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Becton, Dickinson and Company by 62.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,107,317 shares of the medical instruments supplier’s stock worth $266,974,000 after acquiring an additional 424,487 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $227.98 on Friday. The firm has a market cap of $65.46 billion, a PE ratio of 37.87, a PEG ratio of 1.62 and a beta of 0.40. The firm has a fifty day moving average of $232.86 and a 200 day moving average of $233.34. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock buyback program on Tuesday, January 28th that allows the company to buyback 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.82%. Becton, Dickinson and Company’s payout ratio is 69.10%.

Insider Activity

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the transaction, the executive vice president now owns 5,741 shares of the company’s stock, valued at $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Roland Goette sold 4,483 shares of the company’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the transaction, the executive vice president now directly owns 24,345 shares in the company, valued at $5,380,488.45. The trade was a 15.55 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,544 shares of company stock valued at $2,370,309. 0.36% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts recently commented on BDX shares. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, February 12th. Piper Sandler raised their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. Finally, Barclays raised their price target on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.